Chemoinformaics analysis of 3,4,5,6-Tetradehydroyohimbine
| Molecular Weight | 350.418 | nRot | 1 |
| Heavy Atom Molecular Weight | 328.242 | nRig | 26 |
| Exact Molecular Weight | 350.163 | nRing | 5 |
| Solubility: LogS | -4.041 | nHRing | 3 |
| Solubility: LogP | 2.859 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 48 | No. of Aliphatic Hetero Cycles | 3 |
| No. of Heavy Atom | 26 | No. of Aromatic Carbocycles | 1 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 1 |
| No. of Hydrogen atom | 22 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 21 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 13 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 14 |
| nHA | 5 | APOL | 54.3454 |
| nHD | 1 | BPOL | 27.5246 |
| QED | 0.686 |
| Synth | 4.033 |
| Natural Product Likeliness | 0.778 |
| NR-PPAR-gamma | 0.407 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.127 |
| Pgp-sub | 0.015 |
| HIA | 0.005 |
| CACO-2 | -4.821 |
| MDCK | 0.0000246 |
| BBB | 0.908 |
| PPB | 0.843563 |
| VDSS | 1.084 |
| FU | 0.146435 |
| CYP1A2-inh | 0.892 |
| CYP1A2-sub | 0.842 |
| CYP2c19-inh | 0.518 |
| CYP2c19-sub | 0.352 |
| CYP2c9-inh | 0.707 |
| CYP2c9-sub | 0.293 |
| CYP2d6-inh | 0.081 |
| CYP2d6-sub | 0.707 |
| CYP3a4-inh | 0.926 |
| CYP3a4-sub | 0.486 |
| CL | 10.388 |
| T12 | 0.161 |
| hERG | 0.466 |
| Ames | 0.798 |
| ROA | 0.201 |
| SkinSen | 0.13 |
| Carcinogencity | 0.64 |
| EI | 0.03 |
| Respiratory | 0.916 |
| NR-Aromatase | 0.453 |
| Antiviral | Yes |
| Prediction | 0.718801 |